Suur, M.H.

level patient children study parent -12 complement trial activation csf levels consent il -12 plasma meningiti therapy indinavir infection result disease month complement activation count hospital range child reason shock group value admission nonsurvivor inhibitor 1-inh table survivor protein adherence c 4bp response future cytokine parameter 6 months consent form participation adult treatment complex pediatrics information characteristic capillary leakage immunodeficiency virus infection production procedure system seizure virus limit consent procedure disadvantage correlation baseline tumor necrosis factor interleukin immunol elastase control medication pathway difference trial characteristics blood immunodeficiency advantage relation zidovudine sophia children lactoferrin netherland